Summary
Antimicrobial resistance (AMR) is a major threat to public health, causing 670 000 infections and over 33 000 deaths in Europe alone in 2015. So-called Gram-negative bacteria are particularly tough to treat, as they are encased in a tough outer membrane which effectively stops many antibiotics from getting into the bacteria and killing it. The GNA NOW project aims to address the urgent need for new antibiotics to treat Gram-negative infections by attacking the bacteria in new and different ways. The team will run three programmes in parallel, each focusing on a different drug candidate with an innovative mode of action. All drug candidates will undergo a range of tests to ensure their safety and efficacy and to understand and optimise how they work. The project hopes to complete phase 1 clinical trials for at least one candidate, and advance at least one more to the stage where it is ready to enter clinical trials.
GNA NOW is part of the IMI AMR Accelerator Programme.
Achievements & News
November 2022
Laboratory studies show that a potential antibiotic dubbed NOSO-502 is active against some of the most dangerous drug-resistant bacteria. The...
IMI’s GNA NOW project is looking for a novel antibiotic programme to progress to Investigational New Drug (IND). The deadline for expressions of interest is 18 June.###
The aim of GNA NOW is to advance the development of antibiotics designed to treat infections caused by Gram-negative bacteria. These bugs are particularly tough to treat, as they are encased in a tough outer membrane which effectively stops many antibiotics from getting into the bacteria and killing it.
Now the project has launched a call for expressions of interest for potential antibiotics with a novel mode of action designed to address severe hospital infections caused by certain drug-resistant, Gram-negative bacteria.
Those interested in getting involved should submit a short, non-confidential submission of interest to the project by 18 June. Expressions of interest will be assessed by the GNA NOW Review Committee, which is made up of industry, independent and academic experts and antibiotic drug discovery and development.
The teams behind the top three expressions of interest will then be invited to submit a full dossier to the committee.
Find out more
- Read the article in full
Participants
Show participants on mapEFPIA companies
- Glaxosmithkline Investigacion Y Desarrollo SL, Tres Cantos, Spain
Universities, research organisations, public bodies, non-profit groups
- Bioaster Fondation De Cooperation Scientifique, Lyon, France
- Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany
- Helmholtz-Zentrum Fur Infektionsforschung GMBH, Braunschweig, Germany
- Institut National De La Sante Et De La Recherche Medicale, Paris, France
- Medizinische Universitaet Wien, Vienna, Austria
- North Bristol National Health Service Trust, Bristol, United Kingdom
- The University Of Liverpool, Liverpool, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Nosopharm, Nimes, France
- Stichting Lygature, Utrecht, Netherlands
Third parties
- Universite De Poitiers, Poitiers , France
| Participants | |
|---|---|
| Name | EU funding in € |
| Bioaster Fondation De Cooperation Scientifique | 441 359 |
| Erasmus Universitair Medisch Centrum Rotterdam | 1 198 125 |
| Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | 331 835 |
| Helmholtz-Zentrum Fur Infektionsforschung GMBH | 1 268 750 |
| Institut National De La Sante Et De La Recherche Medicale | 139 688 |
| Medizinische Universitaet Wien | 730 571 |
| North Bristol National Health Service Trust | 2 422 556 |
| Nosopharm | 4 098 421 |
| Stichting Lygature | 725 681 |
| The University Of Liverpool | 897 034 |
| Third parties | |
| Name | Funding in € |
| Universite De Poitiers | 45 975 |
| Total Cost | 12 299 995 |
Kristina Orrling
Stichting Lygature